Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2013 (2013), Article ID 310427, 6 pages
http://dx.doi.org/10.1155/2013/310427
Review Article

Clinical Significance of AFP and PIVKA-II Responses for Monitoring Treatment Outcomes and Predicting Prognosis in Patients with Hepatocellular Carcinoma

Hana Park1,2 and Jun Yong Park3,4,5

1Department of Internal Medicine, CHA Bundang Medical Center, CHA University, Seongnam-si, Republic of Korea
2Institute of Gastroenterology, CHA Bundang Medical Center, CHA University, Seongnam-si, Republic of Korea
3Department of Internal Medicine, Yonsei University College of Medicine, 134 Sinchon-dong, Seodaemun-gu, Seoul, Republic of Korea
4Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea
5Yonsei Liver Cancer Special Clinic, Yonsei University College of Medicine, Seoul, Republic of Korea

Received 21 November 2013; Accepted 9 December 2013

Academic Editor: Mohammad Ahmad al-Shatouri

Copyright © 2013 Hana Park and Jun Yong Park. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K.-H. Han and S. H. Ahn, “How to predict HCC development in patients with chronic B viral liver disease?” Intervirology, vol. 48, no. 1, pp. 23–28, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. J. M. Llovet, A. M. di Bisceglie, J. Bruix et al., “Design and endpoints of clinical trials in hepatocellular carcinoma,” Journal of the National Cancer Institute, vol. 100, no. 10, pp. 698–711, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. E. A. Eisenhauer, P. Therasse, J. Bogaerts et al., “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1),” European Journal of Cancer, vol. 45, no. 2, pp. 228–247, 2009. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Furuse, H. Ishii, K. Nakachi, E. Suzuki, S. Shimizu, and K. Nakajima, “Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma,” Cancer Science, vol. 99, no. 1, pp. 159–165, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. B. K. Kim, S. H. Ahn, J. S. Seong et al., “Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma,” Liver International, vol. 31, no. 3, pp. 369–376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. P. J. Johnson, “The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma,” Clinics in Liver Disease, vol. 5, no. 1, pp. 145–159, 2001. View at Google Scholar · View at Scopus
  7. Y. Inagaki, W. Tang, M. Makuuchi, K. Hasegawa, Y. Sugawara, and N. Kokudo, “Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin,” Liver International, vol. 31, no. 1, pp. 22–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. R. Bloomer, T. A. Waldmann, K. R. McIntire, and G. Klatskin, “alpha-fetoprotein in noneoplastic hepatic disorders,” Journal of the American Medical Association, vol. 233, no. 1, pp. 38–41, 1975. View at Publisher · View at Google Scholar · View at Scopus
  9. J. R. Bloomer, T. A. Waldmann, K. R. McIntire, and G. Klatskin, “Serum α fetoprotein in patients with massive hepatic necrosis,” Gastroenterology, vol. 72, no. 3, pp. 479–482, 1977. View at Google Scholar · View at Scopus
  10. K. Hamamura, Y. Shiratori, S. Shiina et al., “Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein,” Cancer, vol. 88, no. 7, pp. 1557–1564, 2000. View at Google Scholar
  11. Y. Koike, Y. Shiratori, S. Sato et al., “Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients,” Cancer, vol. 91, no. 3, pp. 561–569, 2001. View at Google Scholar
  12. L. Zhou, J. Liu, and F. Luo, “Serum tumor markers for detection of hepatocellular carcinoma,” World Journal of Gastroenterology, vol. 12, no. 8, pp. 1175–1181, 2006. View at Google Scholar · View at Scopus
  13. G. Malaguarnera, M. Giordano, I. Paladina, M. Berretta, A. Cappellani, and M. Malaguarnera, “Serum markers of hepatocellular carcinoma,” Digestive Diseases and Sciences, vol. 55, no. 10, pp. 2744–2755, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. H. Park, S. U. Kim, J. Y. Park et al., “Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma,” Liver International, 2013. View at Publisher · View at Google Scholar
  15. K. Kishi, T. Sonomura, K. Mitsuzane et al., “Time courses of PIVKA-II and AFP levels after hepatic artery embolization and hepatic artery infusion against hepatocellular carcinoma: relation between the time course and tumor necrosis,” Radiation Medicine, vol. 10, no. 5, pp. 189–195, 1992. View at Google Scholar · View at Scopus
  16. Y. Aoyagi, M. Oguro, M. Yanagi et al., “Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma,” Cancer, vol. 77, no. 9, pp. 1781–1786, 1996. View at Google Scholar
  17. N. Kokudo and M. Makuuchi, “Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines,” Journal of Gastroenterology, vol. 44, no. 19, pp. 119–121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Nakagawa, T. Seki, T. Shiro et al., “Clinicopathologic significance of protein induced vitamin K absence or antagonist II and α-fetoprotein in hepatocellular carcinoma,” International Journal of Oncology, vol. 14, no. 2, pp. 281–286, 1999. View at Google Scholar · View at Scopus
  19. F. Yamashita, M. Tanaka, S. Satomura, and K. Tanikawa, “Prognostic significance of Lens culinaris agglutinin A—reactive α- fetoprotein in small hepatocellular carcinomas,” Gastroenterology, vol. 111, no. 4, pp. 996–1001, 1996. View at Google Scholar · View at Scopus
  20. Y. E. Chon, G. H. Choi, M. H. Lee et al., “Combined measurement of preoperative α-fetoprotein and des-γ-carboxy prothrombin predicts recurrence after curative resection in patients with hepatitis-B-related hepatocellular carcinoma,” International Journal of Cancer, vol. 131, no. 10, pp. 2332–2341, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. S. H. Kang, Y. Kim do, S. M. Jeon et al., “Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels,” European Journal of Gastroenterology & Hepatology, vol. 24, no. 7, pp. 849–856, 2012. View at Publisher · View at Google Scholar
  22. Y. K. Lee, S. U. Kim, Y. Kim do et al., “Prognostic value of alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization,” BMC Cancer, vol. 13, article 5, 2013. View at Publisher · View at Google Scholar
  23. M. H. Lee, S. U. Kim, D. Y. Kim et al., “Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma,” Journal of Gastroenterology and Hepatology, vol. 27, no. 2, pp. 313–322, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. H. Toyoda, T. Kumada, T. Tada et al., “Prognostic significance of a combination of pre- and post-treatment tumor markers for hepatocellular carcinoma curatively treated with hepatectomy,” Journal of Hepatology, vol. 57, no. 6, pp. 1251–1257, 2012. View at Publisher · View at Google Scholar
  25. A. Nanashima, N. Taura, T. Abo et al., “Tumor marker levels before and after curative treatment of hepatocellular carcinoma as predictors of patient survival,” Digestive Diseases and Sciences, vol. 56, no. 10, pp. 3086–3100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Yamamoto, H. Imamura, Y. Matsuyama et al., “Significance of alpha-fetoprotein and des-γ-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy,” Annals of Surgical Oncology, vol. 16, no. 10, pp. 2795–2804, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. T. Masuda, T. Beppu, K. Horino et al., “Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma,” Journal of Surgical Oncology, vol. 102, no. 5, pp. 490–496, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Nanashima, Y. Sumida, S. Tobinaga et al., “Postoperative changes in protein-induced vitamin K absence or antagonist II levels after hepatectomy in patients with hepatocellular carcinoma: relationship to prognosis,” HPB, vol. 8, no. 2, pp. 137–141, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. W. H. Park, J. H. Shim, S. B. Han et al., “Clinical utility of des-gamma-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization,” Journal of Vascular and Interventional Radiology, vol. 23, no. 7, pp. 927–936, 2012. View at Publisher · View at Google Scholar
  30. T. Kuzuya, Y. Asahina, K. Tsuchiya et al., “Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma,” Oncology, vol. 81, no. 3-4, pp. 251–258, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Nakazawa, H. Hidaka, J. Takada et al., “Early increase in alpha-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib,” European Journal of Gastroenterology & Hepatology, vol. 25, no. 6, pp. 683–689, 2013. View at Publisher · View at Google Scholar
  32. A. Riaz, K. Memon, F. H. Miller et al., “Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation,” Journal of Hepatology, vol. 54, no. 4, pp. 695–704, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. M. M. Arnold, L. Kreel, A. C. Wallace, and A. K. C. Li, “Distribution of lipiodol and evidence for tumor necrosis in hepatocellular carcinoma,” American Journal of Clinical Pathology, vol. 97, no. 3, pp. 405–410, 1992. View at Google Scholar · View at Scopus
  34. K. Yamamoto, H. Imamura, Y. Matsuyama et al., “AFP, AFP-L3, DCP, and GP73 as markers for monitoring treatment response and recurrence and as surrogate markers of clinicopathological variables of HCC,” Journal of Gastroenterology, vol. 45, no. 12, pp. 1272–1282, 2010. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Nakazawa, S. Adachi, M. Kitano et al., “Potential prognostic benefits of radiotherapy as an initial treatment for patients with unresectable advanced hepatocellular carcinoma with invasion to intrahepatic large vessels,” Oncology, vol. 73, no. 1-2, pp. 90–97, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Murata, H. Suzuki, H. Okano, T. Oyamada, Y. Yasuda, and A. Sakamoto, “Hypoxia-induced des-γ-carboxy prothrombin production in hepatocellular carcinoma,” International Journal of Oncology, vol. 36, no. 1, pp. 161–170, 2010. View at Publisher · View at Google Scholar · View at Scopus